Wireless communication with chaos

Peer reviewedPublisher PD

Dynamic Morphing of Smart Trusses and Mechanisms Using Fuzzy and Neuro-Fuzzy Techniques

In the present investigation, the principles of dynamic morphing of smart truss structures and mechanisms are discussed. A possible way in order to find the optimal geometry of the structure for the enhancement of structural performance in terms of vibration control is sought. The vibrations of the host dynamic structures are monitored by controllers which are based on the principles of Mamdani-type fuzzy inference and Sugeno-type adaptive neuro-fuzzy inference. More specifically, the objective of the present study is a design, tuning, and an application of robust intelligent control mechanisms by means of the suppression of structural vibrations for several types of excitation forces. The proposed models are discretized by using a finite element method. For the time integration of the equations of motion, the Newmark-β method is used. The calculations and the analysis are conducted within the Matlab environment by using the Adaptive Neuro-Fuzzy Inference System (ANFIS) tool, which is included in the fuzzy toolbox. The controllers are tested with different excitation forces applied on a truss-shaped structure. The control outputs are applied on each time of the simulation in order to achieve the lowest possible deformation and to prevent potential damage or corruption of the structure. The same principles are used for the dynamic morphing of structures and mechanisms. The proposed formulation can be applied, among many others, on smart irrigation systems such as spray booms, on radio-telescope bases, on the spars of smart wings, on aircraft wings etc

Valvulotomy of the great saphenous vein in ex situ non-reversed and in situ setting: a multicenter post-market study to assess the safety and efficacy of the AndraValvulotome™”

Purpose To evaluate the safety and technical success of the AndraValvulotome™ device (Andramed GmbH, Reutlingen, Germany) in patients with peripheral arterial disease (PAD) requiring bypass surgery using the great saphenous vein (GSV) as graft. Methods This was a multicenter, post-market observational study conducted in 2021 in 11 German centers. Safety and efficacy data were prospectively collected and analyzed. Primary endpoints were the absence of device-related serious adverse events until 30 ± 7 days follow-up, the clinical efficacy of valvulotomy, which was defined as pulsatile blood flow in the bypass and the number of insufficiently destroyed vein valves. Secondary endpoints were the number of valvulotomy passages, the primary patency rate of the venous bypass (determined by a color-duplex sonography showing a normal blood flow through the bypass and absence of stenosis or occlusion), and the primary technical success defined as the absence of product-specific (serious) adverse events and clinical efficacy. Results Fifty-nine patients were enrolled. The mean age of the patients was 71 years (46–91), and 74.6% were males. The vein material used for bypass grafting had a median length of 47.5 cm (range 20–70 cm) with a median diameter of 5.0 mm (range 3–6 mm) and 4.0 mm (range 2–6 mm) in the proximal and distal segments, respectively. The technical success rate was 96.6%. The primary patency rate was 89.9% at 30 days follow-up. The clinical efficacy was rated as very good in 81% of patients, fair in 17%, and poor in 2%. Between 1 and 5 (average 2.9) valvulotome passages were performed. One product-related serious adverse event was recorded (bypass vein dissection). Conclusion The AndraValvulotome™ can be considered a safe and effective device to disrupt venous valves during in situ non-reversed bypass surgeries using GSV grafts in patients with PAD

Review of post-process optical form metrology for industrial-grade metal additive manufactured parts

The scope of this review is to investigate the main post-process optical form measurement technologies available in industry today and to determine whether they are applicable to industrial-grade metal additive manufactured parts. An in-depth review of the operation of optical three-dimensional form measurement technologies applicable to metal additive manufacturing is presented, with a focus on their fundamental limitations. Looking into the future, some alternative candidate measurement technologies potentially applicable to metal additive manufacturing will be discussed, which either provide higher accuracy than currently available techniques but lack measurement volume, or inversely, which operate in the appropriate measurement volume but are not currently accurate enough to be used for industrial measurement

Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.The FAST (food allergy-specific immunotherapy) project aims at developing safe and effective subcutaneous immunotherapy for fish allergy, using recombinant hypoallergenic carp parvalbumin, Cyp c 1.Preclinical characterization and good manufacturing practice (GMP) production of mutant Cyp (mCyp) c 1.Escherichia coli-produced mCyp c 1 was purified using standard chromatographic techniques. Physicochemical properties were investigated by gel electrophoresis, size exclusion chromatography, circular dichroism spectroscopy, reverse-phase high-performance liquid chromatography and mass spectrometry. Allergenicity was assessed by ImmunoCAP inhibition and basophil histamine release assay, immunogenicity by immunization of laboratory animals and stimulation of patients' peripheral blood mononuclear cells (PBMCs). Reference molecules were purified wild-type Cyp c 1 (natural and/or recombinant). GMP-compliant alum-adsorbed mCyp c 1 was tested for acute toxicity in mice and rabbits and for repeated-dose toxicity in mice. Accelerated and real-time protocols were used to evaluate stability of mCyp c 1 as drug substance and drug product.Purified mCyp c 1 behaves as a folded and stable molecule. Using sera of 26 double-blind placebo-controlled food-challenge-proven fish-allergic patients, reduction in allergenic activity ranged from 10- to 5,000-fold (1,000-fold on average), but with retained immunogenicity (immunization in mice/rabbits) and potency to stimulate human PBMCs. Toxicity studies revealed no toxic effects and real-time stability studies on the Al(OH)3-adsorbed drug product demonstrated at least 20 months of stability.The GMP drug product developed for treatment of fish allergy has the characteristics targeted for in FAST: i.e. hypoallergenicity with retained immunogenicity. These results have warranted first-in-man immunotherapy studies to evaluate the safety of this innovative vaccine.info:eu-repo/grantAgreement/EC/FP7/20187

Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study

Background Gastrostomy feeding is commonly used to support patients with amyotrophic lateral sclerosis who develop severe dysphagia. Although recommended by both the American Academy of Neurology and the European Federation of Neurological Societies, currently little evidence indicates the optimum method and timing for gastrostomy insertion. We aimed to compare gastrostomy insertion approaches in terms of safety and clinical outcomes. Methods In this large, longitudinal, prospective cohort study (ProGas), we enrolled patients with a diagnosis of definite, probable, laboratory supported, or possible amyotrophic lateral sclerosis who had agreed with their treating clinicians to undergo gastrostomy at 24 motor neuron disease care centres or clinics in the UK. The primary outcome was 30-day mortality after gastrostomy. This study was registered on the UK Clinical Research Network database, identification number 9923. Findings Between Nov 2, 2010, and Jan 31, 2014, 345 patients were recruited of whom 330 had gastrostomy. 163 (49%) patients underwent percutaneous endoscopic gastrostomy, 121 (37%) underwent radiologically inserted gastrostomy, 43 (13%) underwent per-oral image-guided gastrostomy, and three (1%) underwent surgical gastrostomy. 12 patients (4%, 95% CI 2·1–6·2) died within the first 30 days after gastrostomy: five (3%) of 163 after percutaneous endoscopic gastrostomy, four (3%) of 121 after radiologically inserted gastrostomy, and three (7%) of 43 after per-oral image-guided gastrostomy (p=0·46). Including repeat attempts in 14 patients, 21 (6%) of 344 gastrostomy procedures could not be completed: 11 (6%) of 171 percutaneous endoscopic gastrostomies, seven (6%) of 121 radiologically inserted gastrostomies, and three (6%) of 45 per-oral image-guided gastrostomies (p=0·947). Interpretation The three methods of gastrostomy seemed to be as safe as each other in relation to survival and procedural complications. In the absence of data from randomised trials, our findings could inform clinicians and patients in reaching decisions about gastrostomy and will stimulate further research into the nutritional management in patients with amyotrophic lateral sclerosis

Measurement of CPCP asymmetries in B0→ϕKS0B^0\to \phi K^0_S decays with Belle II

We present a measurement of time-dependent rate asymmetries in $B^0\to \phi K^0_S$ decays to search for non-standard-model physics in $b\to q \overline{q}s$ transitions. The data sample is collected with the Belle II detector at the SuperKEKB asymmetric-energy $e^{+}e^{-}$ collider in 2019-2022 and contains $(387\pm 6)\times 10^6$ bottom-antibottom mesons from $\Upsilon(4S)$ resonance decays. We reconstruct $162\pm17$ signal events and extract the charge-parity ($CP$) violating parameters from a fit to the distribution of the proper-decay-time difference of the two $B$ mesons. The measured direct and mixing-induced $CP$ asymmetries are $A=0.31\pm0.20\pm0.05$ and $S=0.54\pm0.26^{+0.06}_{-0.08}$, respectively, where the first uncertainties are statistical and the second are systematic. The results are compatible with the $CP$ asymmetries observed in $b\to c\overline{c} s$ transitions

Measurement of the τ\tau-lepton mass with the Belle~II experiment

We present a measurement of the $\tau$-lepton mass using a sample of about 175 million $e^+e^- \to \tau^+\tau^-$ events collected with the Belle II detector at the SuperKEKB $e^+e^-$ collider at a center-of-mass energy of $10.579\,\mathrm{Ge\kern -0.1em V}$. This sample corresponds to an integrated luminosity of $190\,\mathrm{fb^{-1}}$. We use the kinematic edge of the $\tau$ pseudomass distribution in the decay ${\tau^-\to\pi^-\pi^+\pi^-\nu_\tau}$ and measure the $\tau$ mass to be $1777.09 \pm 0.08 \pm 0.11 \,\mathrm{Me\kern -0.1em V\!/c^2}$, where the first uncertainty is statistical and the second systematic. This result is the most precise to date

Precise measurement of the Ds+D^+_s lifetime at Belle II

We measure the lifetime of the $D_s^+$ meson using a data sample of 207 fb$^{-1}$ collected by the Belle II experiment running at the SuperKEKB asymmetric-energy $e^+ e^-$ collider. The lifetime is determined by fitting the decay-time distribution of a sample of $116\times 10^3$ $D_s^+\rightarrow\phi\pi^+$ decays. Our result is \tau^{}_{D^+_s} = (498.7\pm 1.7\,^{+1.1}_{-0.8}) fs, where the first uncertainty is statistical and the second is systematic. This result is significantly more precise than previous measurements.Comment: 7 pages, 4 figures, to be submitted to Physical Review Letter

Observation of B→D(∗)K−KS0{B\to D^{(*)} K^- K^{0}_S} decays using the 2019-2022 Belle II data sample

We present a measurement of the branching fractions of four $B^{0,-}\to D^{(*)+,0} K^- K^{0}_S$ decay modes. The measurement is based on data from SuperKEKB electron-positron collisions at the $\Upsilon(4S)$ resonance collected with the Belle II detector and corresponding to an integrated luminosity of ${362~\text{fb}^{-1}}$. The event yields are extracted from fits to the distributions of the difference between expected and observed $B$ meson energy to separate signal and background, and are efficiency-corrected as a function of the invariant mass of the $K^-K_S^0$ system. We find the branching fractions to be: $$\text{B}(B^-\to D^0K^-K_S^0)=(1.89\pm 0.16\pm 0.10)\times 10^{-4},$$ $$\text{B}(\overline B{}^0\to D^+K^-K_S^0)=(0.85\pm 0.11\pm 0.05)\times 10^{-4},$$ $$\text{B}(B^-\to D^{*0}K^-K_S^0)=(1.57\pm 0.27\pm 0.12)\times 10^{-4},$$ $$\text{B}(\overline B{}^0\to D^{*+}K^-K_S^0)=(0.96\pm 0.18\pm 0.06)\times 10^{-4},$$ where the first uncertainty is statistical and the second systematic. These results include the first observation of $\overline B{}^0\to D^+K^-K_S^0$, $B^-\to D^{*0}K^-K_S^0$, and $\overline B{}^0\to D^{*+}K^-K_S^0$ decays and a significant improvement in the precision of $\text{B}(B^-\to D^0K^-K_S^0)$ compared to previous measurements